{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:41:33Z","timestamp":1792190493152,"version":"4.4.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Natural Fund Project","award":["81572434"],"award-info":[{"award-number":["81572434"]}]},{"name":"Ministry of Science and Technology, National Science and Technology Major Special Project: Prevention and Treatment of Major Infectious Diseases such as AIDS and Viral Hepatitis","award":["2018ZX10723204-007-001"],"award-info":[{"award-number":["2018ZX10723204-007-001"]}]},{"name":"Young Medical Elites","award":["Tianjin Health Commission, 2018.12-2020.1"],"award-info":[{"award-number":["Tianjin Health Commission, 2018.12-2020.1"]}]},{"name":"Young Innovative Talents","award":["Tianjin Medical University Cancer Institute and Hospital, 2017.1-2019.12"],"award-info":[{"award-number":["Tianjin Medical University Cancer Institute and Hospital, 2017.1-2019.12"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Isocitrate dehydrogenase 1\/2 (IDH1\/2), BAP1, ARID1A and PBRM1 have been reported as the most frequent mutant genes in intrahepatic cholangiocarcinoma (ICC), and their relationships with clinicopathological features and prognosis were researched in this study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We collected clinical data of 130 ICC patients from January 2012 to December 2017. The IDH1\/2 mutation and loss of BAP1, ARID1A and PBRM1 expressions were detected by DNA sequencing or immunohistochemical methods, and histological subtype of ICCs was determined by hematoxylin-eosin, Alcian blue and S100P staining.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      IDH1\/2 mutation was related to decreased preoperative serum total bilirubin (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.039), ferritin (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.000) and higher histological differentiation (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.024), and was associated with prolonged disease-free survival (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.009) and a trend toward increased overall survival (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.126) in small duct type of ICCs. Immunohistochemical staining results of MsMab-1 were generally consistent with DNA sequencing for IDH1\/2 mutant in ICCs (\u03ba\u2009=\u20090.691). Only BAP1 expression loss was correlated to prolonged disease-free survival (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.031) and overall survival (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.041) in large duct type of ICCs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IDH1\/2 mutation is a favorable predictor and may be related to iron metabolism in small duct type of ICCs. Furthermore, we suggest that the detection of IDH1\/2 mutation is indispensable to determine targeted therapy in small duct type ICCs, while it is not necessary in large duct of ICCs. MsMab-1 is a relatively effective multi-specific antibody against IDH1\/2 mutant in ICCs. BAP1 expression loss was correlated with improved prognosis only in large duct type ICCs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-06804-6","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T09:03:53Z","timestamp":1586941433000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Distinct clinical and prognostic implication of IDH1\/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma"],"prefix":"10.1186","volume":"20","author":[{"given":"Bingqi","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqiang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ti","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlong","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huikai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,15]]},"reference":[{"key":"6804_CR1","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1053\/ejso.1999.0660","volume":"25","author":"ZE El Rassi","year":"1999","unstructured":"El Rassi ZE, Partensky C, Scoazec JY, et al. Peripheral cholangiocarcinoma: presentation, diagnosis, pathology and management. Eur J Surg Oncol. 1999;25:375\u201380.","journal-title":"Eur J Surg Oncol"},{"key":"6804_CR2","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1007\/s11605-011-1419-8","volume":"15","author":"YY Li","year":"2011","unstructured":"Li YY, Li H, Lv P, et al. Prognostic value of cirrhosis for intrahepatic cholangiocarcinoma after surgical treatment. J Gastrointest Surg. 2011;15:608\u201313.","journal-title":"J Gastrointest Surg"},{"key":"6804_CR3","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1158\/1055-9965.EPI-05-0811","volume":"15","author":"KA McGlynn","year":"2006","unstructured":"McGlynn KA, Tarone RE, El-Serag HB. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomark Prev. 2006;15:1198\u2013203.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"6804_CR4","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1038\/ng.2813","volume":"45","author":"Y Jiao","year":"2013","unstructured":"Jiao Y, Pawlik TM, Anders RA, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet. 2013;45:1470\u20133.","journal-title":"Nat Genet"},{"key":"6804_CR5","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.18632\/oncotarget.1943","volume":"5","author":"M Simbolo","year":"2014","unstructured":"Simbolo M, Fassan M, Ruzzenente A, et al. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. Oncotarget. 2014;5:2839\u201352.","journal-title":"Oncotarget"},{"key":"6804_CR6","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1245\/s10434-014-3828-x","volume":"21","author":"AX Zhu","year":"2014","unstructured":"Zhu AX, Borger DR, Kim Y, et al. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets. Ann Surg Oncol. 2014;21:3827\u201334.","journal-title":"Ann Surg Oncol"},{"key":"6804_CR7","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1038\/onc.2012.315","volume":"32","author":"P Wang","year":"2013","unstructured":"Wang P, Dong Q, Zhang C, et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene. 2013;32:3091\u2013100.","journal-title":"Oncogene"},{"key":"6804_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00428-018-2478-y","volume":"474","author":"S Sarcognato","year":"2019","unstructured":"Sarcognato S, Gringeri E, Fassan M, et al. Prognostic role of BAP-1 and PBRM-1 expression in intrahepatic cholangiocarcinoma. Virchows Arch. 2019;474:29\u201337.","journal-title":"Virchows Arch"},{"key":"6804_CR9","doi-asserted-by":"publisher","first-page":"7119","DOI":"10.1038\/s41598-018-25669-1","volume":"8","author":"M Simbolo","year":"2018","unstructured":"Simbolo M, Vicentini C, Ruzzenente A, et al. Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma. Sci Rep. 2018;8:7119.","journal-title":"Sci Rep"},{"key":"6804_CR10","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1097\/PAS.0000000000000670","volume":"40","author":"A Hayashi","year":"2016","unstructured":"Hayashi A, Misumi K, Shibahara J, et al. Distinct Clinicopathologic and genetic features of 2 histologic subtypes of intrahepatic Cholangiocarcinoma. Am J Surg Pathol. 2016;40:1021\u201330.","journal-title":"Am J Surg Pathol"},{"key":"6804_CR11","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1097\/PAS.0b013e31802b34b6","volume":"31","author":"S Aishima","year":"2007","unstructured":"Aishima S, Kuroda Y, Nishihara Y, et al. Proposal of progression model for intrahepatic cholangiocarcinoma: clinicopathologic differences between hilar type and peripheral type. Am J Surg Pathol. 2007;31:1059\u201367.","journal-title":"Am J Surg Pathol"},{"key":"6804_CR12","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1002\/hep.25595","volume":"55","author":"M Komuta","year":"2012","unstructured":"Komuta M, Govaere O, Vandecaveye V, et al. Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology. 2012;55:1876\u201388.","journal-title":"Hepatology"},{"key":"6804_CR13","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/modpathol.2017.22","volume":"30","author":"M Akita","year":"2017","unstructured":"Akita M, Fujikura K, Ajiki T, et al. Dichotomy in intrahepatic cholangiocarcinomas based on histologic similarities to hilar cholangiocarcinomas. Mod Pathol. 2017;30:986\u201397.","journal-title":"Mod Pathol"},{"key":"6804_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/liv.14093","volume":"39","author":"T Kendall","year":"2019","unstructured":"Kendall T, Verheij J, Gaudio E, et al. Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int. 2019;39:7\u201318.","journal-title":"Liver Int"},{"key":"6804_CR15","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/modpathol.2013.241","volume":"27","author":"JY Liau","year":"2014","unstructured":"Liau JY, Tsai JH, Yuan RH, et al. Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features. Mod Pathol. 2014;27:1163\u201373.","journal-title":"Mod Pathol"},{"key":"6804_CR16","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1126\/science.1164382","volume":"321","author":"DW Parsons","year":"2008","unstructured":"Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807\u201312.","journal-title":"Science"},{"key":"6804_CR17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s10014-012-0085-1","volume":"29","author":"M Arai","year":"2012","unstructured":"Arai M, Nobusawa S, Ikota H, et al. Frequent IDH1\/2 mutations in intracranial chondrosarcoma: a possible diagnostic clue for its differentiation from chordoma. Brain Tumor Pathol. 2012;29:201\u20136.","journal-title":"Brain Tumor Pathol"},{"key":"6804_CR18","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1172\/JCI67266","volume":"123","author":"AS McKenney","year":"2013","unstructured":"McKenney AS, Levine RL. Isocitrate dehydrogenase mutations in leukemia. J Clin Invest. 2013;123:3672\u20137.","journal-title":"J Clin Invest"},{"key":"6804_CR19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1634\/theoncologist.2011-0386","volume":"17","author":"DR Borger","year":"2012","unstructured":"Borger DR, Tanabe KK, Fan KC, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012;17:72\u20139.","journal-title":"Oncologist"},{"key":"6804_CR20","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","volume":"18","author":"ME Figueroa","year":"2010","unstructured":"Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18:553\u201367.","journal-title":"Cancer Cell"},{"key":"6804_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","volume":"19","author":"W Xu","year":"2011","unstructured":"Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of \u03b1-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19:17\u201330.","journal-title":"Cancer Cell"},{"key":"6804_CR22","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/ng.2323","volume":"44","author":"S Pe\u00f1a-Llopis","year":"2012","unstructured":"Pe\u00f1a-Llopis S, Vega-Rub\u00edn-de-Celis S, Liao A, et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet. 2012;44:751\u20139.","journal-title":"Nat Genet"},{"key":"6804_CR23","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1008433","volume":"363","author":"KC Wiegand","year":"2010","unstructured":"Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;363:1532\u201343.","journal-title":"N Engl J Med"},{"key":"6804_CR24","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/his.12632","volume":"67","author":"Q Rao","year":"2015","unstructured":"Rao Q, Xia QY, Wang ZY, et al. Frequent co-inactivation of the SWI\/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours. Histopathology. 2015;67:121\u20139.","journal-title":"Histopathology"},{"key":"6804_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115383","volume":"9","author":"CR Churi","year":"2014","unstructured":"Churi CR, Shroff R, Wang Y, et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One. 2014;9:e115383.","journal-title":"PLoS One"},{"key":"6804_CR26","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/his.13127","volume":"70","author":"K Misumi","year":"2017","unstructured":"Misumi K, Hayashi A, Shibahara J, et al. Intrahepatic cholangiocarcinoma frequently shows loss of BAP1 and PBRM1 expression, and demonstrates specific clinicopathological and genetic characteristics with BAP1 loss. Histopathology. 2017;70:766\u201374.","journal-title":"Histopathology"},{"key":"6804_CR27","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/NEN.0b013e31822713f0","volume":"70","author":"M Preusser","year":"2011","unstructured":"Preusser M, W\u00f6hrer A, Stary S, et al. Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens. J Neuropathol Exp Neurol. 2011;70:715\u201323.","journal-title":"J Neuropathol Exp Neurol"},{"key":"6804_CR28","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002491","volume":"95","author":"J Andrici","year":"2016","unstructured":"Andrici J, Goeppert B, Sioson L, et al. Loss of BAP1 expression occurs frequently in intrahepatic Cholangiocarcinoma. Medicine (Baltimore). 2016;95:e2491.","journal-title":"Medicine (Baltimore)"},{"key":"6804_CR29","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1634\/theoncologist.2015-0210","volume":"20","author":"L Goyal","year":"2015","unstructured":"Goyal L, Govindan A, Sheth RA, et al. Prognosis and Clinicopathologic features of patients with advanced stage Isocitrate dehydrogenase (IDH) mutant and IDH wild-type intrahepatic Cholangiocarcinoma. Oncologist. 2015;20:1019\u201327.","journal-title":"Oncologist"},{"key":"6804_CR30","doi-asserted-by":"publisher","first-page":"e00079","DOI":"10.1128\/MCB.00079-17","volume":"37","author":"MJ Kerins","year":"2017","unstructured":"Kerins MJ, Vashisht AA, Liang BX, et al. Fumarate mediates a chronic proliferative signal in Fumarate Hydratase-inactivated Cancer cells by increasing transcription and translation of ferritin genes. Mol Cell Biol. 2017;37:e00079\u201317.","journal-title":"Mol Cell Biol"},{"key":"6804_CR31","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S0306-9877(02)00342-0","volume":"60","author":"S Johnson","year":"2003","unstructured":"Johnson S. Do mitochondria regulate cellular iron homeostasis through citric acid and haem production? Implications for cancer and other diseases. Med Hypotheses. 2003;60:106\u201311.","journal-title":"Med Hypotheses"},{"key":"6804_CR32","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/PAI.0000000000000342","volume":"25","author":"S Babakoohi","year":"2017","unstructured":"Babakoohi S, Lapidus RG, Faramand R, et al. Comparative analysis of methods for detecting Isocitrate dehydrogenase 1 and 2 mutations and their metabolic consequence, 2-Hydroxyglutarate, in different neoplasms. Appl Immunohistochem Mol Morphol. 2017;25:334\u20137.","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"6804_CR33","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","volume":"15","author":"S Rizvi","year":"2018","unstructured":"Rizvi S, Khan SA, Hallemeier CL, et al. Cholangiocarcinoma-evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15:95\u2013111.","journal-title":"Nat Rev Clin Oncol"},{"key":"6804_CR34","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1021\/acsmedchemlett.7b00421","volume":"9","author":"J Popovici-Muller","year":"2018","unstructured":"Popovici-Muller J, Lemieux RM, Artin E, et al. Discovery of AG-120 (Ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med Chem Lett. 2018;9:300\u20135.","journal-title":"ACS Med Chem Lett"},{"key":"6804_CR35","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1038\/leu.2017.84","volume":"31","author":"LM Kats","year":"2017","unstructured":"Kats LM, Vervoort SJ, Cole R, et al. A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML. Leukemia. 2017;31:1466\u201370.","journal-title":"Leukemia"},{"key":"6804_CR36","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1158\/2159-8290.CD-15-1442","volume":"6","author":"SK Saha","year":"2016","unstructured":"Saha SK, Gordan JD, Kleinstiver BP, et al. Isocitrate dehydrogenase mutations confer Dasatinib hypersensitivity and SRC dependence in intrahepatic Cholangiocarcinoma. Cancer Discov. 2016;6:727\u201339.","journal-title":"Cancer Discov"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-06804-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-06804-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-06804-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T19:46:46Z","timestamp":1618429606000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-06804-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,15]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["6804"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-06804-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.22983\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.22983\/v2","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,15]]},"assertion":[{"value":"2 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Medical Ethics Committee of Tianjin Medical University Cancer Institute and Hospital approved this study (Approval No.: bc2019065). Informed consents were obtained from all patients or their legal guardian.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The typical ICC patient with IDH1 mutation provided informed written consent to the use of clinical data and MR images for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"318"}}